Can-Fite BioPharma
Targeted Drugs for Cancer and Inflammatory Diseases
StartupCan-Fite BioPharma is a Petah Tikva-based startup in the Health Tech & Life Sciences sector, established in 1994. Targeted Drugs for Cancer and Inflammatory Diseases. The company has raised a total of $98.45M across 19 funding rounds, currently at the Public stage. Can-Fite BioPharma was founded by Ilan Cohn, PhD. Key investors include Undisclosed Investor(s), CKD Pharmaceuticals. The company has 11-50 employees. Core technologies: Biologicals, Molecules.
With $98.45M in total funding, Can-Fite BioPharma is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQPetah Tikva
- DistrictCenter District
- Last Round$3M
- Undisclosed Investor(s)
- CKD Pharmaceuticals
Ilan Cohn, PhDCo-founder & Chairman
185 articles covered by sources including finance.yahoo.com,
www.pharmaceutical-technology.com,
www.businesswire.com,
www.clinicaltrialsarena.com,
www.nasdaq.com.
What does Can-Fite BioPharma do?
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary drug candidates in phase II and phase III clinical development that address inflammatory, liver, and metabolic diseases. Can-Fite's platform technology utilizes the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory, cancer, and other pathological body cells, whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company's compounds bind with nM affinity to the A3AR and initiate deregulation of the NF-kB and Wnt signal transduction pathways, resulting in anti-inflammatory and anticancer effects.
How much funding has Can-Fite BioPharma raised?
Can-Fite BioPharma has raised $98.45M in total funding across 19 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), CKD Pharmaceuticals.
Who founded Can-Fite BioPharma?
Can-Fite BioPharma was founded in 1994 by Ilan Cohn, PhD (Co-founder & Chairman).
What sector is Can-Fite BioPharma in?
Can-Fite BioPharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers, Life Sciences, Pharmaceuticals.
Where is Can-Fite BioPharma located?
Can-Fite BioPharma is based in Bareket St 10, Petah Tikva, Israel, Center District. The company also has offices abroad.